Search Results

2027 BioCapital Standard (2)

2027 BioMidwest Elite (2)

2027 BioMidwest Standard (1)

2027 Bio NC Standard (2)

2027 Biotech Bay Elite (3)

2027 Biotech Bay Standard (1)

2027 Biotech Beach Elite (3)

2027 Biotech Beach Standard (2)

2027 Genetown Elite (2)

2027 Genetown Standard (4)

2027 Pharm Country Elite (1)

2027 Pharm Country Standard (3)

40 Under 40 (2)

Academia (267)

Accelerated approval (12)

ADA (6)

Adcomms (17)

Allergies (34)

Alliances (7207)

ALS (54)

Alzheimer's disease (269)

Antibody-drug conjugate (ADC) (202)

Approvals (1126)

Artificial intelligence (256)

ASCO (61)

Autoimmune disease (121)

Automation (15)

Bankruptcy (61)

Belgium (4)

Best Places to Work (889)

BIO (40)

Biologics (18)

BIOSECURE Act (17)

Biosimilars (47)

BioSpace Insights (85)

Biotechnology (27)

Bispecific (6)

Bladder cancer (40)

Brain cancer (24)

Breast cancer (88)

Cancer (1244)

Cardiovascular disease (147)

Career advice (781)

Career pathing (37)

CAR-T (133)

CDC (7)

CDMO (102)

Cell-line development (1)

Cell therapy (336)

Cervical cancer (9)

Clinical research (7270)

Collaboration (713)

Commercialization (11)

Company closure (7)

Compensation (45)

Complete response letters (52)

COVID-19 (443)

CRISPR (30)

CRO (4)

C-suite (520)

Cystic fibrosis (30)

Data (1044)

Decentralized trials (1)

Denatured (27)

Depression (52)

Dermatology (28)

Diabetes (69)

Diagnostics (576)

Digital health (5)

Diversity (4)

Diversity, equity & inclusion (19)

Drug discovery (170)

Drug pricing (51)

Drug shortages (1)

Duchenne muscular dystrophy (105)

Earnings (5516)

Editorial (42)

Employer branding (8)

Employer resources (70)

ESMO (54)

Events (11764)

Executive appointments (400)

Eye disease (3)

FDA (1753)

Fragile X (2)

Friedreich's ataxia (3)

Frontotemporal dementia (8)

Funding (674)

Gene editing (83)

Generative AI (30)

Gene therapy (328)

GLP-1 (287)

Government (514)

Grass and pollen (1)

Guidances (30)

Healthcare (1216)

Hematology (31)

HIV (13)

Huntington's disease (39)

Idiopathic pulmonary fibrosis (2)

IgA nephropathy (33)

Immunology and inflammation (181)

Immuno-oncology (47)

Indications (25)

Infectious disease (536)

Inflammatory bowel disease (46)

Inflation Reduction Act (3)

Influenza (25)

Intellectual property (54)

Interviews (144)

IPO (1754)

IRA (11)

Job creations (1136)

Job search strategy (675)

JPM (46)

Kidney cancer (5)

Kidney disease (30)

Labor market (90)

Layoffs (279)

Leadership (42)

Legal (712)

Licensing (24)

Liver cancer (12)

Longevity (14)

Lung cancer (158)

Lung diease (5)

Lymphoma (63)

Machine learning (25)

Management (22)

Manufacturing (414)

Marketing (2)

MASH (50)

Medical affairs (1)

Medical device (377)

Medtech (385)

Mergers & acquisitions (3164)

Metabolic disorders (377)

mRNA (104)

Multiple sclerosis (24)

Multispecific (3)

NASH (7)

Netherlands (3)

Neurodegenerative disease (166)

Neuropsychiatric disorders (52)

Neuroscience (704)

Neurotech (2)

NextGen: Class of 2026 (895)

Non-profit (279)

Now hiring (62)

Obesity (229)

Opinion (220)

Ovarian cancer (36)

Pain (30)

Pancreatic cancer (60)

Parkinson's disease (72)

Partnered (15)

Patents (103)

Patient recruitment (118)

Patient selection (12)

Peanut (6)

People (11393)

Peptides (7)

Pharmaceutical (8)

Phase 1 (2711)

Phase 2 (3484)

Phase 3 (2230)

Pipeline (1644)

Policy (160)

Postmarket research (114)

Preclinical (1019)

Press Release (53)

Prostate cancer (42)

Psychedelics (49)

Radiopharmaceuticals (86)

Rare diseases (469)

Real estate (1509)

Recruiting (40)

Regenerative medicine (6)

Regulatory (2708)

Reports (20)

Research institute (304)

Resumes & cover letters (153)

Rett syndrome (6)

RNA editing (17)

RSV (19)

Schizophrenia (35)

Series A (155)

Series B (93)

Service/supplier (2)

Sickle cell disease (23)

Special edition (22)

Spinal muscular atrophy (19)